Sound Pharmaceuticals' hearing loss drug success in Phase II
This article was originally published in Scrip
Executive Summary
Privately held, biopharmaceutical company Sound Pharmaceuticals (SPI) has released positive data Phase II data for its sensorineural hearing loss drug SPI-1005.